期刊
PSYCHO-ONCOLOGY
卷 24, 期 4, 页码 402-407出版社
WILEY-BLACKWELL
DOI: 10.1002/pon.3602
关键词
breast cancer; cognition; depression; adjuvant therapy; tamoxifen; aromatase inhibitors; hormone therapy
Background ObjectiveBreast cancer survivors receiving hormone treatment and/or endorsing histories of receiving chemotherapy report changes in their cognitive capacity, which is often not supported by formal testing. To address these conflicting reports, this study examined survivors' applied cognitive capacity and its association with hormone treatment, depression, and selected demographics. MethodsA descriptive, correlational, cross-sectional survey design was employed. There were 357 women who completed a survey comprised of 69 questions. The survey included both investigator-developed questions and instruments from the PROMIS (R) system. ResultsThere were significant main effects for hormone therapy, race, and depression. Depression explained the largest portion of variance of the perceived decreases in cognitive function among breast cancer survivors. ConclusionsSurvivor complaints of changes in cognitive function may be a predictor for evaluating the presence of mood disorders and less a function of hormone therapy or chemotherapy history. Copyright (c) 2014 John Wiley & Sons, Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据